| ID | 10343 |
| Vaccine Name | Vidprevtyn |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Protein subunit |
| Vaccine Status | Phase 3 |
| Manufacturer | Sanofi Pasteur, GlaxoSmithKline |
| Year of Manufacturing | 2021 |
| Manufacturing Country | USA |
| Age | 18 years and above |
| Dosage | 2 doses 14 days apart |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | SARS-CoV-2 protein |
| Description | NA |
| Approving Organisation | NA |
| Collaborating Organisation | GlaxoSmithKline |
| Other Countries | USA, Colombia, Honduras, Japan, Kenya |
| Trade Name | VAT00002, VAT00008 |
| PMID | NA |
| Clinical Trial ID | NCT04904549 |
| Reference Link | https://clinicaltrials.gov/ct2/show/NCT04904549 |
| Additional Links | https://www.sanofi.com/en/our-covid-19-vaccine-candidates/phase-3-clinical-trial-for-COVID19-recombinant-protein-vaccine-candidate
|